DENVER, July 16 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Wednesday, July 21, 2010, at 4:00 PM EDT to discuss the Company’s announced major collaboration and investment from the ELITech Group, a Paris, France-based, privately held group of companies and worldwide manufacturer and distributor of in-vitro diagnostic equipment and reagents. The Form 8-K related to this transaction has been filed with the Securities and Exchange Commission today, July 16, 2010, and will be followed by a press release next Monday, July 19, 2010.
Corgenix invites all those interested in hearing management’s discussion to join the call by dialing:
U.S. attendees: (800) 894-5910 | |
International attendees: +1 785 424 1052 | |
Conference code is: CORGENIX | |
A question-and-answer session will follow the presentation by Corgenix management.
A replay will be available for 30 days following the call by dialing (800) 839-2382 for U.S. participants and +1 402 220 7201 for international participants.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at www.corgenix.com.
SOURCE Corgenix Medical Corporation
